Related Experiment Videos
Endotracheal continuous positive airway pressure after rescue surfactant therapy
Insights
Two-thirds of premature infants over 31 weeks gestation with hyaline membrane disease (HMD) can be successfully treated with endotracheal continuous positive airway pressure (ETCPAP) after rescue surfactant therapy. This approach offers favorable outcomes for respiratory support.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Critical Care
Background:
- Hyaline membrane disease (HMD) is a significant cause of respiratory distress in premature infants.
- Established HMD often requires intensive respiratory support.
- Rescue surfactant therapy is a critical intervention for HMD.
Purpose of the Study:
- To evaluate the efficacy of endotracheal continuous positive airway pressure (ETCPAP) following rescue surfactant therapy in premature infants (>31 weeks gestation) with HMD.
- To identify factors predicting treatment failure.
Main Methods:
- Retrospective analysis of 46 premature infants with HMD.
- Assessment of ETCPAP tolerance post-surfactant treatment.
- Comparison of prenatal/postnatal characteristics and outcomes between success and failure groups.
- Logistic regression to identify failure predictors.
Main Results:
- 65.2% of infants were successfully managed with ETCPAP after rescue surfactant.
- Predictors of failure included Cesarean section, higher 1-minute Apgar, and higher FiO2.
- Failure reasons: hypoxemia (56.3%), hypercapnia (31.2%), apnea (12.5%).
- Success group showed significantly shorter intubation, oxygen use, and hospital stay.
Conclusions:
- ETCPAP is a viable management strategy for selected premature infants (>31 weeks) with HMD requiring rescue surfactant.
- Successful ETCPAP use is associated with improved respiratory support duration and hospital stay.
- Further research may refine patient selection for this treatment approach.
Objective:
To determine if premature infants greater than 31 weeks of gestation with established hyaline membrane disease (HMD) can be treated with endotracheal continuous positive airway pressure (ETCPAP) after rescue surfactant replacement therapy.
Study Design:
Retrospective study of 46 premature infants (>31 weeks of gestation) admitted to Texas Children's Hospital with HMD. Tolerance to ETCPAP after surfactant replacement was evaluated. Prenatal and postnatal characteristics and outcome were compared in the success and failure groups. Multiple logistic regression was used to determine predictive factors associated with failure.
Results:
Thirty infants (65.2%) were successfully treated with rescue surfactant and ETCPAP. Cesarean section, higher 1-minute Apgar score, and higher FiO2 level at entry were independent predictors of failure to remain on CPAP due to hypoxemia (56.3%), hypercapnia (31.2%), and apnea (12.5%). In the success group duration of intubation (p < 0.001), oxygen administration (p < 0.01), >40% oxygen requirement (p < 0.001), hospital stay (p < 0.05), and respiratory support on day 7 (p < 0.001) were significantly favorable.
Conclusion:
Two thirds of infants greater than 31 weeks of gestation, with HMD needing rescue surfactant treatment, can be successfully managed with ETCPAP.